BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang ZY, Hong D, Nam SH, Kim JM, Paik YH, Joh JW, Kwon CH, Park JB, Choi GS, Jang KY. SIRT1 regulates oncogenesis via a mutant p53-dependent pathway in hepatocellular carcinoma. J Hepatol. 2015;62:121-130. [PMID: 25131770 DOI: 10.1016/j.jhep.2014.08.007] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.9] [Reference Citation Analysis]
Number Citing Articles
1 Laguna JC, Alegret M, Roglans N. Simple sugar intake and hepatocellular carcinoma: epidemiological and mechanistic insight. Nutrients 2014;6:5933-54. [PMID: 25533006 DOI: 10.3390/nu6125933] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
2 Schulte L, Scheiner B, Voigtländer T, Koch S, Schweitzer N, Marhenke S, Ivanyi P, Manns MP, Rodt T, Hinrichs JB, Weinmann A, Pinter M, Vogel A, Kirstein MM. Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma. Liver Int 2019;39:714-26. [PMID: 30663219 DOI: 10.1111/liv.14048] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 11.5] [Reference Citation Analysis]
3 An Y, Wang B, Wang X, Dong G, Jia J, Yang Q. SIRT1 inhibits chemoresistance and cancer stemness of gastric cancer by initiating an AMPK/FOXO3 positive feedback loop. Cell Death Dis 2020;11:115. [PMID: 32051395 DOI: 10.1038/s41419-020-2308-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
4 Luo D, Fan H, Ma X, Yang C, He Y, Ge Y, Jiang M, Xu Z, Yang L. miR-1301-3p Promotes Cell Proliferation and Facilitates Cell Cycle Progression via Targeting SIRT1 in Gastric Cancer. Front Oncol 2021;11:664242. [PMID: 33987098 DOI: 10.3389/fonc.2021.664242] [Reference Citation Analysis]
5 Simioni C, Zauli G, Martelli AM, Vitale M, Sacchetti G, Gonelli A, Neri LM. Oxidative stress: role of physical exercise and antioxidant nutraceuticals in adulthood and aging. Oncotarget. 2018;9:17181-17198. [PMID: 29682215 DOI: 10.18632/oncotarget.24729] [Cited by in Crossref: 136] [Cited by in F6Publishing: 104] [Article Influence: 45.3] [Reference Citation Analysis]
6 Farcas M, Gavrea AA, Gulei D, Ionescu C, Irimie A, Catana CS, Berindan-Neagoe I. SIRT1 in the Development and Treatment of Hepatocellular Carcinoma. Front Nutr 2019;6:148. [PMID: 31608282 DOI: 10.3389/fnut.2019.00148] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
7 Wang YS, Du L, Liang X, Meng P, Bi L, Wang YL, Wang C, Tang B. Sirtuin 4 Depletion Promotes Hepatocellular Carcinoma Tumorigenesis Through Regulating Adenosine-Monophosphate-Activated Protein Kinase Alpha/Mammalian Target of Rapamycin Axis in Mice. Hepatology 2019;69:1614-31. [PMID: 30552782 DOI: 10.1002/hep.30421] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
8 Vijayakumaran R, Tan KH, Miranda PJ, Haupt S, Haupt Y. Regulation of Mutant p53 Protein Expression. Front Oncol 2015;5:284. [PMID: 26734569 DOI: 10.3389/fonc.2015.00284] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
9 Wang X, Wu F, Li G, Zhang N, Song X, Zheng Y, Gong C, Han B, He G. Lipid-modified cell-penetrating peptide-based self-assembly micelles for co-delivery of narciclasine and siULK1 in hepatocellular carcinoma therapy. Acta Biomaterialia 2018;74:414-29. [DOI: 10.1016/j.actbio.2018.05.030] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
10 Jiang X, Tan HY, Teng S, Chan YT, Wang D, Wang N. The Role of AMP-Activated Protein Kinase as a Potential Target of Treatment of Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E647. [PMID: 31083406 DOI: 10.3390/cancers11050647] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 13.0] [Reference Citation Analysis]
11 Seydi E, Motallebi A, Dastbaz M, Dehghan S, Salimi A, Nazemi M, Pourahmad J. Selective Toxicity of Persian Gulf Sea Cucumber (Holothuria parva) and Sponge (Haliclona oculata) Methanolic Extracts on Liver Mitochondria Isolated from an Animal Model of Hepatocellular Carcinoma. Hepat Mon. 2015;15:e33073. [PMID: 26977167 DOI: 10.5812/hepatmon.33073] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
12 Yamamoto S, Iwakuma T. Regulators of Oncogenic Mutant TP53 Gain of Function. Cancers (Basel) 2018;11:E4. [PMID: 30577483 DOI: 10.3390/cancers11010004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 9.7] [Reference Citation Analysis]
13 Zhao J, Gray SG, Greene CM, Lawless MW. Unmasking the pathological and therapeutic potential of histone deacetylases for liver cancer. Expert Review of Gastroenterology & Hepatology 2019;13:247-56. [DOI: 10.1080/17474124.2019.1568870] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
14 Jiang H, Zhang X, Tao Y, Shan L, Jiang Q, Yu Y, Cai F, Ma L. Prognostic and clinicopathologic significance of SIRT1 expression in hepatocellular carcinoma. Oncotarget 2017;8:52357-65. [PMID: 28881735 DOI: 10.18632/oncotarget.14096] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
15 Cheng J, Shuai X, Gao J, Cai M, Wang G, Tao K. Prognostic significance of AMPK in human malignancies: A meta-analysis. Oncotarget 2016;7:75739-48. [PMID: 27716618 DOI: 10.18632/oncotarget.12405] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
16 Zhou X, Hao Q, Lu H. Mutant p53 in cancer therapy-the barrier or the path. J Mol Cell Biol. 2019;11:293-305. [PMID: 30508182 DOI: 10.1093/jmcb/mjy072] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 64.0] [Reference Citation Analysis]
17 Kanda M, Sugimoto H, Kodera Y. Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol. 2015;21:10584-10597. [PMID: 26457018 DOI: 10.3748/wjg.v21.i37.10584] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 41] [Article Influence: 7.4] [Reference Citation Analysis]
18 Yang H, Zhu R, Zhao X, Liu L, Zhou Z, Zhao L, Liang B, Ma W, Zhao J, Liu J, Huang G. Sirtuin-mediated deacetylation of hnRNP A1 suppresses glycolysis and growth in hepatocellular carcinoma. Oncogene 2019;38:4915-31. [PMID: 30858544 DOI: 10.1038/s41388-019-0764-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 10.5] [Reference Citation Analysis]
19 Guo M, Li N, Zheng J, Wang W, Wu Y, Han X, Guo J, Chen W, Bai Z, Bai W, Wu J. Epigenetic Regulation of Hepatocellular Carcinoma Progression through the mTOR Signaling Pathway. Can J Gastroenterol Hepatol 2021;2021:5596712. [PMID: 34123955 DOI: 10.1155/2021/5596712] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Yu XN, Chen H, Liu TT, Wu J, Zhu JM, Shen XZ. Targeting the mTOR regulatory network in hepatocellular carcinoma: Are we making headway? Biochim Biophys Acta Rev Cancer 2019;1871:379-91. [PMID: 30951815 DOI: 10.1016/j.bbcan.2019.03.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
21 Kim JO, Kim KH, Song IS, Cheon KS, Kim OH, Lee SC, Lee SK, Kim SJ. Potentiation of the anticancer effects of everolimus using a dual mTORC1/2 inhibitor in hepatocellular carcinoma cells. Oncotarget 2017;8:2936-48. [PMID: 27935857 DOI: 10.18632/oncotarget.13808] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
22 Chen SL, Liu LL, Wang CH, Lu SX, Yang X, He YF, Zhang CZ, Yun JP. Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways. Mol Oncol 2020;14:373-86. [PMID: 31670863 DOI: 10.1002/1878-0261.12593] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
23 Jiang G, Wen L, Zheng H, Jian Z, Deng W. miR-204-5p targeting SIRT1 regulates hepatocellular carcinoma progression: miR-204-5p inhibits hepatocellular carcinoma progression. Cell Biochem Funct 2016;34:505-10. [DOI: 10.1002/cbf.3223] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
24 Wang Q, Cheng ST, Chen J. HBx mediated Increase of SIRT1 Contributes to HBV-related Hepatocellular Carcinoma Tumorigenesis. Int J Med Sci 2020;17:1783-94. [PMID: 32714081 DOI: 10.7150/ijms.43491] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Tsai HH, Lai HY, Chen YC, Li CF, Huang HS, Liu HS, Tsai YS, Wang JM. Metformin promotes apoptosis in hepatocellular carcinoma through the CEBPD-induced autophagy pathway. Oncotarget 2017;8:13832-45. [PMID: 28099155 DOI: 10.18632/oncotarget.14640] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 7.3] [Reference Citation Analysis]
26 Almajali B, Al-Jamal HAN, Taib WRW, Ismail I, Johan MF, Doolaanea AA, Ibrahim WN. Thymoquinone, as a Novel Therapeutic Candidate of Cancers. Pharmaceuticals (Basel) 2021;14:369. [PMID: 33923474 DOI: 10.3390/ph14040369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Ren J, Hu J, Cheng S, Yu H, Wong VKW, Law BYK, Yang Y, Huang Y, Liu Y, Chen W, Cai X, Tang H, Hu Y, Zhang W, Liu X, Long Q, Zhou L, Tao N, Zhou H, Yang Q, Ren F, He L, Gong R, Huang A, Chen J. SIRT3 restricts hepatitis B virus transcription and replication through epigenetic regulation of covalently closed circular DNA involving suppressor of variegation 3‐9 homolog 1 and SET domain containing 1A histone methyltransferases. Hepatology 2018;68:1260-76. [DOI: 10.1002/hep.29912] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 11.0] [Reference Citation Analysis]
28 Wu Y, Meng X, Huang C, Li J. Emerging role of silent information regulator 1 (SIRT1) in hepatocellular carcinoma: a potential therapeutic target. Tumor Biol 2015;36:4063-74. [DOI: 10.1007/s13277-015-3488-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
29 Ou L, Wang D, Zhang H, Yu Q, Hua F. Decreased Expression of miR-138-5p by lncRNA H19 in Cervical Cancer Promotes Tumor Proliferation. Oncol Res 2018;26:401-10. [PMID: 28797320 DOI: 10.3727/096504017X15017209042610] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
30 Yue X, Zhao Y, Xu Y, Zheng M, Feng Z, Hu W. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy. J Mol Biol. 2017;429:1595-1606. [PMID: 28390900 DOI: 10.1016/j.jmb.2017.03.030] [Cited by in Crossref: 118] [Cited by in F6Publishing: 107] [Article Influence: 29.5] [Reference Citation Analysis]
31 Mello T, Simeone I, Galli A. Mito-Nuclear Communication in Hepatocellular Carcinoma Metabolic Rewiring. Cells 2019;8:E417. [PMID: 31060333 DOI: 10.3390/cells8050417] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]